Delving into the Latest Updates on Wyeth BioPharma with Synapse

Overview

主要目的：评估中国健康受试者接受recifercept 冻干制剂单剂皮下给药后的 PK 次要目的： 1)评估中国健康受试者接受recifercept 冻干制剂单剂皮下给药的安全性和耐受性 2)评估中国健康受试者接受recifercept 冻干制剂单剂皮下给药的免疫原性

[Translation]

Primary objective: To evaluate the PK of a single subcutaneous dose of a lyophilized formulation of recifercept in healthy Chinese subjects Secondary objectives: 1) To evaluate the safety and tolerability of a single subcutaneous dose of a lyophilized formulation of recifercept in healthy Chinese subjects 2) To evaluate the immunogenicity of a single subcutaneous dose of a lyophilized formulation of recifercept in healthy Chinese subjects

Start Date-

Sponsor / Collaborator

Pfizer Inc.

[+2]

100 Clinical Results associated with Wyeth BioPharma

Login to view more data

0 Patents (Medical) associated with Wyeth BioPharma

Login to view more data

100 Deals associated with Wyeth BioPharma

Login to view more data

100 Translational Medicine associated with Wyeth BioPharma

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

6

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Cilmostim ( nAChRα1/β1/δ/γ )	Neoplasms More	Discontinued
MG-1104 ( factor IX )	Hemophilia B More	Pending
GNI-250	Neoplasms More	Pending
SDF-1 (Genetics Institute)	HIV Infections More	Pending
MIF (Genetics Institute) ( MIF )	Neoplasms More	Pending